GT Biopharma (GTBP) Requests Withdrawal of Form S-1 Registration Statement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement
February 25, 2025 7:00 AM ESTSAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the Company) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that it has filed a Request for Withdrawal with the U.S. Securities and Exchange Commission (SEC) with respect to the withdrawal of the Companys Registration Statement on Form S-1 (File No. 333-284032) that it filed with the SEC originally on December 23, 2024. The Registration Statement has not been declared effective by the SEC,... More
